糖心视频

One of the technologies that has potential to change the world is genome editing, and there are a number of companies in the genetics space building tools to edit life’s underlying code.

Follow Crunchbase News on &

Durham, NC-based is one of those companies. A Friday afternoon by the company indicates that it’s raising $110 million in equity funding for what’s likely to be its Series B round. So far, the company has raised $88.07 million since the first check was signed on May 25th of this year. At this point, there are 40 investors involved in the offering, and the company has yet to close $21.92 million of the round’s funding target.

To date, the company has raised $25.7 million in known outside funding in . That round was led by and had participation from , , , and . The company was founded in 2006 and raised money that year, but that initial round is not listed in Crunchbase. Its SEC filing is not available because it was filed on paper and hasn’t been digitized.

Why does this matter? Precision BioSciences is a technological leader in the emerging field of gene editing. The company developed and patented a process called , which is based on a proprietary synthetic enzyme it calls ARC nuclease. It is similar in mechanism to other , but just smaller and more precise. According to its , the company is exploring applications of ARCUS in areas such as cancer immunotherapy, gene therapy, and agriculture.

In its from 2015, the company said: “ARCUS is Precision鈥檚 latest proprietary genome editing platform and the first to combine the target site flexibility of a TALEN or with the exquisite site specificity and small size of a homing endonuclease, overcoming the major shortcomings of earlier editing technologies.”

Precision BioSciences is not the only gene editing company to raise sizable rounds recently. Here are some examples:

• , which uses CRISPR base editing to develop genetic medicines and treat diseases, raised $87 million in April and May in a – Series A round led by ARCH Venture Partners.
• , which uses gene editing technology to engineer immune cells for cancer immunotherapies, raised co-led by Sequoia Capital and 3sbio this past May.
• Back in February of this year, , another gene editing technology company based in Boulder, CO, raised round.

Precision BioScience’s $110 million round is certainly large, but it’s not eye-popping in the world of life sciences investing. However, the round serves as the latest evidence that investors continue to see opportunity in gene editing and the therapies it can enable.

滨濒濒耻蝉迟谤补迟颈辞苍:听